Substance / Medication

Pimozide

Overview

Active Ingredient
pimozide
RxNorm CUI
8331

Indications

Pimozide tablets, USP are indicated for the suppression of motor and phonic tics in patients with Tourette’s Disorder who have failed to respond satisfactorily to standard treatment. Pimozide Tablets, USP are not intended as a treatment of first choice nor is it intended for the treatment of tics that are merely annoying or cosmetically troublesome. Pimozide Tablets, USP should be reserved for use in Tourette’s Disorder patients whose development and/or daily life function is severely compromise

Labeler: Endo USA, Inc.Updated: 2017-11-25T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

1. Pimozide is contraindicated in the treatment of simple tics or tics other than those associated with Tourette’s Disorder. 2. Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patient

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Pimozide for schizophrenia or related psychoses.
Mothi Meghana, Sampson Stephanie · Cochrane Database Syst Rev · 2013
PMID: 24194433Meta-AnalysisFull text (PMC)
Pimozide for tics in Tourette's syndrome.
Pringsheim Tamara, Marras Connie · Cochrane Database Syst Rev · 2009
PMID: 19370666Meta-AnalysisFull text (PMC)
Pimozide for schizophrenia or related psychoses.
Rathbone J, McMonagle T · Cochrane Database Syst Rev · 2007
PMID: 17636692Meta-Analysis
Pimozide for schizophrenia or related psychoses.
Sultana A, McMonagle T · Cochrane Database Syst Rev · 2000
PMID: 10908518Meta-Analysis
Pimozide for schizophrenia or related psychoses.
Sultana A, McMonagle T · Cochrane Database Syst Rev · 2000
PMID: 10796672Meta-Analysis
Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy.
Friedman Joseph I, Lindenmayer Jean-Pierre, Alcantara Frances et al. · Neuropsychopharmacology · 2011
PMID: 21346734RCTFull text (PMC)
Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia.
Gunduz-Bruce Handan, Oliver Stephen, Gueorguieva Ralitza et al. · Schizophr Res · 2013
PMID: 23219861Observational
Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (Orap) in rats.
Ishiwari Keita, Betz Adrienne, Weber Suzanne et al. · Pharmacol Biochem Behav · 2005
PMID: 15680188Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Pimozide (substance)
SNOMED CT
386848009
UMLS CUI
C0031935
RxNorm CUI
8331
Labeler
Endo USA, Inc.

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.